Skip to main content
Premium Trial:

Request an Annual Quote

Dieter Schmidt-Base, Elizabeth Holbrook, Richard Gill, Ronald Casciato, Herbert Fritsche


Tripos has promoted Dieter Schmidt-Base to senior vice president of worldwide sales from vice president of European sales, while Elizabeth Holbrook, formerly vice president of sales in North America and Pacific Rim, has left the company, Tripos said. In his new role, Schmidt-Base will oversee the restructuring of Tripos’ sales organization to create a stronger focus on product and service sales, the company said. Schmidt-Base will be responsible for creating a new group of business development specialists focused on enterprise informatics service contracts and drug discovery research contracts. Before joining Tripos, Schmidt-Base worked as a research associate at the University of Wisconsin in Madison on organo-lead compounds for protein structure determination.

Richard Gill has joined Signet Laboratories as president and CEO, succeeding founder Ronald Casciato, who will assume the role of executive chairman. Gill was most recently the president and CEO of AnVil, which ceased operations in June 2003.

Herbert Fritsche has been tapped as the chairman of Health Discovery’s scientific advisory board. Fritsche is a professor of laboratory medicine and chief of the clinical chemistry section at the University of Texas, MD Anderson Cancer Center in Houston, Texas.


Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.